Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)Breast Cancer Res Treat 2021 Sep 03;[EPub Ahead of Print], LJ Goldstein, M Mansutti, C Levy, JC Chang, S Henry, I Fernandez-Perez, J Prausovà, E Staroslawska, G Viale, B Butler, S McCanna, PA Ruffini, MS Wicha, AF Schott
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.